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ABSTR ACT
PURPOSE: We examined the cross-sectional association between lung function and metabolic syndrome (MetS), independent of fasting immunoreactive 
insulin (F-IRI). 
METHODS: A total of 3,072 middle-aged, apparently healthy subjects who participated in a general health check-up were included. Lung function, 
which was expressed as forced vital capacity (%FVC predicted) or forced expiratory volume in 1 second (FEV1% predicted) was examined. Multivariable 
logistic regression analysis was performed to assess the association between lung function and MetS.
RESULTS: Men with the lowest quartile of FVC% predicted, or those with the lowest quartile of FEV1% predicted, had a 3.5-fold or 2.6-fold increased 
risk of MetS, respectively, compared with those with the highest quartile of FVC% predicted or FEV1% predicted. F-IRI had a positive, significant, and 
independent association with MetS in both sexes. 
CONCLUSION: Impaired lung function increased the risk of MetS, independent of F-IRI and smoking in men, but not in women.
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Introduction
Metabolic syndrome (MetS) is a condition clustered with 
abdominal obesity, elevated glucose and blood pressure, and 
dyslipidemia. It is closely associated with the development of 
type 2 diabetes and cardiovascular disease (CVD).1,2 However, 
the mechanisms involved in the pathways of MetS have not yet 
been completely clarified. There are controversies surrounding 
whether obesity or insulin resistance causes MetS, or whether 
all of these are consequences of inflammation.3,4
On the other hand, reduced lung function is indepen-
dently associated with MetS,5 and impaired lung function 
exists before the development of MetS.6 So, reduced lung 
function and MetS may share the common pathophysiologi-
cal grounds. However, to our knowledge, no studies have 
examined the association between lung function and MetS 
while taking into account insulin concentrations. This study 
has investigated the cross-sectional association between lung 
function and MetS, independent of fasting insulin concentra-
tions, among apparently healthy Japanese men and women.
Materials and Methods
Subjects. The Kurihashi Lifestyle Cohort Study com-
prises a total of 7,363 subjects enrolled in a general health 
examination program at Saitama-ken Saiseikai Kurihashi 
Hospital (Saitama, Japan) from October 2006 to September 
2007. For the current analysis, the following criteria were 
used for excluding individuals: missing data on spirometry 
(n  =  4,677) or fasting insulin concentrations (n  =  3,780); 
 having cancer, endocrine, respiratory, or congestive heart 
disease (n = 172); a diagnosis of diabetes (n = 39); currently 
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under pharmacological treatments for hypertension (n = 421) 
or  dyslipidemia (n = 90); and missing data on relevant covari-
ates (n = 40). Because pharmacological treatments for hyper-
tension, dyslipidemia, and diabetes probably influence insulin 
sensitivity, the patients who had been treated by medications 
for hypertension, dyslipidemia, and diabetes were excluded, 
and the remaining 2,020 men and 1,052 women were used for 
the current data analysis.
Methods. The health check examination of this study 
includes self-administrated questionnaires regarding smoking 
(never = 0; otherwise, pack-years of cigarettes in ever-smokers 
were determined) and alcohol intake (never, occasionally, and 
regularly); physical activity during leisure time (sedentary, 
occasionally, active); a family history of diabetes (yes or no); as 
well as physical examinations, biochemical tests, chest X-rays, 
and electrocardiograms.
Venous blood samples were collected in the morning 
after an overnight fasting state for more than 10 hours.  Fasting 
plasma glucose (FPG) (glucose oxidase method),  fasting 
immunoreactive insulin (F-IRI) (enzyme immunoassay 
method), triglycerides (TG) (enzymatic method), and high-
density  lipoprotein cholesterol (HDL-C) (direct method) were 
measured in the commercial laboratory. The intraassay coeffi-
cient of variation for FPG, F-IRI, TG, and HDL at values of 
5.33 mmol/L, 7.6 μU/mL, 0.44 mmol/L, and 0.90 mmol/L 
was 2.0%, 3.4%, 1.3%, and 1.1%, respectively. The corre-
sponding values for the interassay coefficient of variation was 
0.0%, 2.1%, 0.3%, and 0.4%, respectively.
Systolic blood pressures (sBP) and diastolic blood pres-
sures (dBP) were measured with patients in the sitting position 
after a 5-minute rest using an automated device (OMRON, 
Kyoto, Japan). Waist circumference (Wc) was measured at 
the level of umbilicus at the end of the expiration of a normal 
breath, and with the subject in a standing position.
The International Diabetes Federation’s definition of 
MetS (IDF-MetS)7 was modified and used to identify sub-
jects with MetS in the current study: those with central 
obesity (defined as Wc 90 cm for men and 80 cm for 
women in Japan); and those with any two of the follow-
ing four  factors − 1) raised TG: 1.7 mmol/L; 2) reduced 
HDL: 1.03 mmol/L in men and 1.29 mmol/L in women; 
3) raised BP: sBP  130 mmHg or dBP  85 mmHg; and 
4) raised FPG  5.6 mmol/L.
The pack-years of cigarettes were calculated using the 
Brinkman index, which is defined as the number of cigarettes 
smoked ⋅ day-1 × number of years smoked (to convert to pack-
years, divide by 20).
Lung function. Lung function tests were carried out in 
every participant by an experienced technician using a spi-
rometer (HI-701; CHEST, Tokyo, Japan). The crude data on 
forced vital capacity (FVC) or forced expiratory volume in 
1 second (FEV1) were divided by predicted FVC or predicted 
FEV1, respectively, to yield FVC% predicted and FEV1% 
 predicted. The predicted FVC or predicted FEV1 for men were 
calculated by the formula designed for Japanese individuals by 
the Japanese Respiratory Society8: 
 
FVC (L) = 0.045 × height (cm) - 0.023 × age - 2.258, 
FEV1 (L) = 0.036 × height (cm) - 0.028 × age - 1.178,
 (1)
and for women8: 
 
FVC (L) = 0.032 × height (cm) - 0.018 × age - 2.258,  
FEV1 (L) = 0.022 × height (cm) - 0.022 × age - 0.005.
 (2)
The FVC% predicted and FEV1% predicted were strati-
fied by quartiles in men and women, respectively, and they 
were used in the logistic regression analysis described in the 
following section.
Statistical analysis. Statistical analyses were performed 
and reported separately for men and women. The chi-squared 
test was used to compare proportions, and Student’s t-test was 
used to compare means between independent two groups.
The potential relationship between lung function (FVC% 
predicted, FEV1% predicted) and F-IRI, as well as variables 
defining modified IDF-MetS (FPG, BPs [sBP, dBP], lip-
ids [TG, HDL-C]) was investigated by univariate linear 
regression analysis. As for TG or F-IRI, log transformed 
values were used to obtain the values that follow a normal 
distribution. Next, variables independently associated with 
lung function were analyzed by multivariable linear regres-
sion analysis. The independent variables used in the analysis 
included pack-years of cigarettes and menopause status (only 
for women). Further additional adjustment for F-IRI was 
performed to assess whether the association between lung 
function and identified variables was independent from the 
F-IRI concentrations.
The logistic regression analysis was performed to assess 
what factors, including lung function, related to the presence 
of the modified IDF-MetS. The variables that were identi-
fied as significant in the univariate model were included in 
the multivariable logistic regression model. The independent 
variables used in the analysis included age (continuous), pack-
years of cigarettes (continuous), physical activity during leisure 
time (categorical), alcohol habits (categorical), F-IRI (continu-
ous), FVC% predicted (continuous), FEV1% predicted (con-
tinuous), and (in women only) menopause status (categorical). 
The unadjusted and adjusted odds ratios (ORs) and their 95% 
confidence intervals (CIs) for the presence of modified IDF-
MetS were calculated and reported.
The Kurihashi Lifestyle Cohort Study was approved 
by the Institutional Review Board of Saitama-ken Saiseikai 
Kurihashi Hospital (Saitma, Japan), as well as Tokyo  Women’s 
Medical University (Tokyo, Japan), and written informed 
consent was obtained from the participants.
Data were analyzed with the SPSS statistical package 
for Windows version 21.0 (IBM Corporation, Armonk, NY, 
USA). P-values were based on two-sided tests, and the cut-off 
point for statistical significance was P  0.05.
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Results
Characteristics of study subjects. The participants’ 
mean age was 50 ± 8 years and the mean body mass index 
was 23.2 ± 3.1 kg/m2. The mean FVC% predicted and FEV1% 
predicted were 108% ± 14% and 100% ± 14%, respectively 
(Table  1). Men had significantly worse cardiovascular risk 
profiles and lower FVC% predicted or FEV1% predicted than 
women (Table 1). The proportion of men and women with 
the modified IDF-MetS was 12.9% and 10.6%, respectively.
Lung function and variables related to modified IDF-
MetS. The univariate linear regression analysis showed a sig-
nificant effect of lung function either on the components of 
modified IDF-MetS and on F-IRI in men (Table 2). The com-
ponents of the modified IDF-MetS deteriorated and F-IRI 
increased with declining lung function (Table 2). In women, 
the significant association was shown between FVC% pre-
dicted and FPG, sBP, and F-IRI, and between FEV1% pre-
dicted and HDL-C (Table 2).
The multivariable linear regression analysis showed that 
the relationship between FVC% predicted and the compo-
nents of modified IDF-MetS remained significant after adjust-
ing for smoking (pack years of cigarettes) in men (Table  3). 
However, this significant association remained only for FPG 
and sBP, after making an additional adjustment for F-IRI. The 
 relationship between FEV1% predicted and Wc or HDL-C 
remained  significant after additional adjustment for smok-
ing (pack-years of cigarettes) and F-IRI in men (Table 3). In 
women, the association between FEV1% predicted and sBP 
remained as significant after adjusting for smoking (pack-years 
of cigarettes), menopause, and F-IRI (Table 3).
Lung function and the modified IDF-MetS. The uni-
variate logistic regression analysis showed that smoking (pack-
years of cigarettes), physical activity at leisure time, F-IRI, and 
lung function (FVC% predicted and FEV1% predicted) had 
significant association with the presence of the modified IDF-
MetS in men (Table  4). In women, age, menopause, F-IRI, 
FVC% predicted, and FEV1% predicted had a significant asso-
ciation with modified IDF-MetS (Table 4).
The multivariable logistic regression analysis showed that 
smoking (pack-years of cigarettes), F-IRI, and FVC% predicted 
or FEV1% predicted had a significant and independent asso-
ciation with the presence of the modified IDF-MetS in men 
(Table 5). Men with the lowest quartiles of FVC% predicted 
or of FEV1% predicted had a 1.92-fold or 1.58-fold increased 
risk of modified IDF-MetS compared with those with the 
highest quartiles of FVC% predicted or of FEV1% predicted 
(Table  5). In women, menopause and F-IRI had a positive 
and  independent association with the presence of the modi-
Table 1. Characteristics of men and women analyzed for the study.
TOTAL MEN WOMEN P-VALUE*
number 3,072 2,020 1,052
age (years) 50 ± 8 50 ± 9 50 ± 8 0.811
Body mass index (k/m2) 23.2 ± 3.1 23.7 ± 3.1 22.2 ± 3.1 0.001
Waist circumference (cm) 83.4 ± 8.6 85.2 ± 7.9 79.9 ± 8.7 0.001
Fasting plasma glucose (mmol/l) 5.1 ± 3.1 5.2 ± 0.6 4.9 ± 0.5 0.001
Triglyceride (mmol/l) 1.24 ± 0.80 1.37 ± 0.88 0.99 ± 0.53 0.001
Hdl-cholesterol (mmol/l) 1.49 ± 0.38 1.39 ± 0.36 1.73 ± 0.38 0.001
systolic blood pressure (mmHg) 123 ± 16 124 ± 15 120 ± 16 0.001
diastolic blood pressure (mmHg) 77 ± 12 79 ± 12 72 ± 11 0.001
Fasting immunoreactive insulin (μU/ml) 6.31 ± 3.85 6.65 ± 4.12 5.66 ± 3.15 0.001
Lung function
FVC (l) 3.61 ± 0.80 4.00 ± 0.65 2.87 ± 0.46 0.001
FeV1 (l) 2.86 ± 0.66 3.15 ± 0.58 2.32 ± 0.42 0.001
FVC% predicted 108 ± 14 107 ± 14 110 ± 14 0.001
FeV1% predicted 100 ± 14 99 ± 13 103 ± 14 0.001
Current smoker (%) 28.3 38.3 9.0 0.001
smoking (pack-years of cigarettes) 39 ± 26 40 ± 26 22 ± 17 0.001
physically inactive at leisure time (%) 19.3 20.2 18.3 0.001
**Modified IDF-MetS (%) 12.1 12.9 10.6 0.062
data are presented as the mean ± sd. *Men versus women. 
**Central obesity (defined as Wc  90 cm for men and 80 cm for women in Japan) and any two of the following four factors: 1) raised TG: 1.7 mmol/l; 2) reduced 
Hdl: 1.03 mmol/l in men and 1.29 mmol/l in women; 3) raised blood pressure: systolic blood pressure 130 mmHg or diastolic blood pressure 85 mmHg;  
4) raised fasting plasma glucose 5.6 mmol/l.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; Hdl, high-density lipoprotein; idF-Mets, international diabetes 
Federation—Metabolic syndrome.
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Table 2. Univariate linear regression analysis for variables related to metabolic syndrome from FVC% predicted or FeV1% predicted as 
independent variables.
DEPENDENT VARIABLES FVC% PREDICTED FEV1% PREDICTED
β P-VALUE β P-VALUE
Men
Waist circumference -0.060 0.001 -0.089 0.001
Fasting plasma glucose -0.005 0.001 -0.030 0.120
systolic blood pressure -0.116 0.001 -0.054 0.036
diastolic blood pressure -0.043 0.032 -0.032 0.113
log transformed triglyceride -0.005 0.001 -0.002 0.001
Hdl-cholesterol 0.003 0.001 0.005 0.001
log transformed F-iRi -0.003 0.001 -0.003 0.001
Women
Waist circumference -0.026 0.175 -0.015 0.446
Fasting plasma glucose -0.002 0.049 0.033 0.139
systolic blood pressure -0.145 0.001 -0.026 0.465
diastolic blood pressure -0.049 0.053 -0.034 0.182
log transformed triglyceride -0.001 0.059 -0.001 0.237
Hdl-cholesterol 0.001 0.084 0.002 0.023
log transformed F-iRi -0.001 0.002 -0.004 0.092
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; Hdl, high-density lipoprotein; F-iRi, fasting immunoreactive insulin.
Table 3. Multivariable linear regression analysis to predict variables related to metabolic syndrome from FVC% predicted or FeV1% predicted as 
independent variables.
DEPENDENT VARIABLES FVC% PREDICTED FEV1% PREDICTED
β P-VALUE β P-VALUE
Men
Waist circumference Model 1 -0.055 0.001 -0.082 0.001
Model 2 0.004 0.722 -0.025 0.020
Fasting plasma glucose Model 1 -0.005 0.001 – –
Model 2 -0.002 0.025 – –
systolic blood pressure Model 1 -0.111 0.001 -0.048 0.073
Model 2 -0.069 0.007 – –
diastolic blood pressure Model 1 -0.041 0.042 – –
Model 2 -0.008 0.697 – –
log transformed triglyceride Model 1 -0.001 0.001 -0.002 0.001
Model 2 -0.0005 0.133 -0.001 0.091
Hdl-cholesterol Model 1 0.003 0.001 0.005 0.001
Model 2 0.001 0.126 0.003 0.001
log transformed F-iRi Model 1 -0.003 0.001 -0.003 0.001
Women
Fasting plasma glucose Model 1 0.0005 0.744 – –
systolic blood pressure Model 1 -0.092 0.025 – –
Model 2 -0.084 0.031 – –
Hdl-cholesterol Model 1 – – 0.0005 0.628
Model 2 – – – –
log transformed F-iRi Model 1 -0.0004 0.526 – –
Model 1: adjustment was made for smoking, FVC% predicted, or FeV1% predicted, and menopause (only for women).
Model 2: Model 1 with an additional adjustment for log transformed F-iRi.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; Hdl, high-density lipoprotein; F-iRi, fasting immunoreactive insulin. 
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fied IDF-MetS. However, either FVC% predicted or FEV1% 
 predicted did not have a statistically significant association with 
the presence of the modified IDF-MetS (Table 5).
Discussion
The cross-sectional association between lung function and 
MetS has been previously reported in men and women.5,9-12 
However, it was unknown whether this association occurred 
independently of F-IRI concentrations. In the current study, 
the risk of modified IDF-MetS increased with the reduction 
of lung function, independently of F-IRI and smoking in 
apparently healthy Japanese men, but not in women.
MetS had an association with lung dysfunction9-12 in a 
particularly restrictive pattern, exhibiting an FVC  80% of 
Table 4. Univariate logistic regression analysis predicting the presence of modified IDF–metabolic syndrome.
INDEPENDENT VARIABLES ODDS RATIOS (95% CONFIDENCE  
INTERVALS)
P-VALUE
Men
age (1 year) 1.00 (0.98–1.01) 0.833
smoking (100 pack-years of cigarettes) 1.06 (1.02–1.10) 0.001
Physical activity at leisure time
sedentary versus occasionally 0.75 (0.56–0.99) 0.044
sedentary versus regularly 0.53 (0.36–0.79) 0.002
Alcohol
never versus occasionally 1.40 (0.71–2.77) 0.336
never versus regularly 1.21 (0.61–2.40) 0.588
log transformed F-iRi (1 sd) 3.43 (2.89–4.06) 0.001
FVC% predicted
1st Q versus 4th Q 3.47 (2.30–5.23) 0.001
2nd Q versus 4th Q 2.32 (1.51–3.56) 0.001
3rd Q versus 4th Q 1.61 (1.03–2.52) 0.039
FEV1% predicted
1st Q versus 4th Q 2.63 (1.79–3.87) 0.001
2nd Q versus 4th Q 1.61 (1.07–2.42) 0.023
3rd Q versus 4th Q 1.33 (0.87–2.03) 0.186
Women
age (1 year) 1.06 (1.04–1.09) 0.001
smoking (100 pack-years of cigarettes) 1.01 (0.86–1.20) 0.876
Physical activity at leisure time
sedentary versus occasionally 0.94 (0.62–1.43) 0.775
sedentary versus occasionally 0.71 (0.37–1.34) 0.292
Alcohol
never versus occasionally 0.69 (0.31–1.52) 0.356
never versus regularly 1.31 (0.46–3.74) 0.618
Menopause (yes) 2.87 (1.70–4.87) 0.001
log transformed F-iRi (1 sd) 4.31 (3.31–5.61) 0.001
FVC% predicted
1st Q versus 4th Q 2.81 (1.59–5.32) 0.001
2nd Q versus 4th Q 1.69 (0.89–3.24) 0.111
3rd Q versus 4th Q 1.78 (0.94–3.39) 0.079
FEV1% predicted
1st Q versus 4th Q 1.87 (1.06–3.29) 0.030
2nd Q versus 4th Q 1.58 (0.89–2.83) 0.120
3rd Q versus 4th Q 0.98 (0.52–1.85) 0.959
Abbreviations: F-iRi, fasting immunoreactive insulin; Q, quartiles; sd, standard deviation.
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Table 5. Multivariable logistic regression analysis predicting the presence of modified IDF-metabolic syndrome.
INDEPENDENT VARIABLES ODDS RATIOS (95% CONFIDENCE  
INTERVALS)
P-VALUE
Men
Model 1 smoking (100 pack-years of cigarettes) 1.06 (1.02–1.10) 0.005
Physical activity
sedentary versus occasionally 0.85 (0.62–1.17) 0.311
sedentary versus regularly 0.72 (0.46–1.13) 0.151
log transformed F-iRi (1 sd) 3.28 (2.74–3.91) 0.001
FVC% predicted
1st Q versus 4th Q 1.92 (1.22–3.04) 0.005
2nd Q versus 4th Q 1.62 (1.01–2.58) 0.045
3rd Q versus 4th Q 1.24 (0.76–2.02) 0.391
Model 2 smoking (100 pack-years of cigarettes) 1.06 (1.02–1.10) 0.006
Physical activity
sedentary versus occasionally 0.84 (0.61–1.16) 0.297
sedentary versus regularly 0.72 (0.46–1.13) 0.152
log transformed F-iRi (1 sd) 3.36 (2.81–4.01) 0.001
FEV1% predicted
1st Q versus 4th Q 1.58 (1.02–2.46) 0.041
2nd Q versus 4th Q 1.36 (0.87–2.14) 0.182
3rd Q versus 4th Q 1.33 (0.83–2.11) 0.233
Women
Model 1 age (1 year) 1.01 (0.96–1.07) 0.605
Menopause (yes) 2.75 (1.20–6.32) 0.017
log transformed F-iRi (1 sd) 4.57 (3.25–6.43) 0.001
FVC% predicted
1st Q versus 4th Q 1.74 (0.78–3.87) 0.173
2nd Q versus 4th Q 1.24 (0.53–2.92) 0.626
3rd Q versus 4th Q 1.27 (0.56–2.89) 0.566
Model 2 age (1 year) 1.02 (0.97–1.07) 0.523
Menopause (yes) 2.73 (1.18–6.31) 0.019
log transformed F-iRi (1 sd) 4.74 (3.35–6.69) 0.001
FEV1% predicted
1st Q versus 4th Q 1.30 (0.58–2.90) 0.523
2nd Q versus 4th Q 1.62 (0.74–3.53) 0.226
3rd Q versus 4th Q 0.51 (0.21–1.26) 0.144
Abbreviations: F-iRi, fasting immunoreactive insulin; Q, quartiles; sd, standard deviation.
the predicted value and an FEV1-to-FVC ratio 0.7. Due to 
a very small number of cases with serious lung impairments 
(the proportion of people with an FVC  80% was 8.4% and 
that with an FEV1-to-FVC ratio 0.7 was 6.8%), we could 
not analyze our data in the same manner as was conducted 
in  previous studies.9-12 Nevertheless, lung dysfunction with 
restrictive, rather than obstructive, patterns seemed to have 
stronger associations with modified IDF-MetS in our study, 
although the reason for this was not known.
Lung dysfunction has also been reported as a risk fac-
tor for developing diabetes,13 hypertension,14 and CVD15 in 
 prospective studies. These associations may be partly explained 
by the adverse effect associated with lung volumes and com-
pliance due to obesity,5,9,10 systemic inflammation,16,17 insulin 
resistance,18 and adverse early-life exposures.19 Leone et  al20 
have reported that the association between lung dysfunction 
and MetS based on the definition according to the American 
Heart Association/National Heart, Lung, and Blood Institute 
(in which abdominal obesity accounts for three of five compo-
nents of MetS) was predominantly due to abdominal obesity.21 
In the current study, abdominal obesity, which is the essential 
component of IDF-MetS, was  independently  associated with 
Lung function, insulin and metabolic syndrome 
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lung function, and lung function was  independently associated 
with modified IDF-MetS in men. These findings might be a 
reflection of the fact that obesity leads to a decrease in chest 
wall compliance and an increase in peripheral airway resis-
tance. Systemic inflammation markers such as C-reactive pro-
tein (CRP), leukocytes, and fibrinogen were associated with 
lung dysfunction,16,22,23 while biomarkers of inflammation and 
endothelial dysfunction have been associated with MetS.22,23 
Moreover, elevated serum leptin levels are reported in subjects 
of normal body weight with impaired lung  function,24 and this 
would promote inflammation. Alternatively, the decreased 
skeletal muscle strength leads to a decline in lung function and 
an increase in insulin resistance, because skeletal muscles play 
an important role in insulin-mediated glucose disposal.25
In contrast to Japanese men, almost no association was 
shown between lung function and the components of MetS, 
including Wc, in Japanese women. There may be a  difference 
in the way that the distribution of fat affects the thoracic 
mechanics in men when compared to women.26 Women 
develop peripheral adiposity more often, whereas men are more 
prone to central obesity.27 Visceral fat is an important source 
of free fatty acids and inflammatory mediators that affect 
hepatic glucose and fat metabolism, and it likely contributes 
to the development of hepatic insulin resistance.28 In women, 
body fat distribution shift to a more male pattern following 
menopause. Since both pre- and postmenopause women were 
included in our study, women with various patterns of adipos-
ity were included, and this may have influenced our results. 
Moreover, the sex hormone, estrogen, may influence the asso-
ciation between lung function and MetS in women.
The strength of the study is that the association between 
lung function and MetS together with F-IRI was evaluated 
in both men and women, separately. In addition, we used 
predicted FVC% and FEV1% with the formula defined by 
the Japan Respiratory Society.8 Since we repeated the same 
analysis using the international formula for the predicted 
FVC as well as for the FEV1, according to Baldwin et  al29 
and Berglund et  al,30 our results did not change. There are 
several limitations. First, there was selection bias since not all 
participants had data pertaining to lung function and F-IRI. 
As shown in Table 6, the individuals analyzed in the study 
were older but had healthier CVD risk profiles than those 
who were not  analyzed in the study. Thus, our results should 
be carefully generalized to the broader population. Second, as 
discussed above, elevated CRP (as a marker of inflammation) 
is associated with lung dysfunction, insulin resistance, and 
MetS.22,23 However, we were unable to assess this relationship 
due to a lack of data for CRP in our study. Third, although 
Table 6. Comparison of characteristics between individuals who were analyzed and not analyzed in the study.
INDIVIDUALS ANALYZED  
IN THE STUDY
INDIVIDUALS NOT  
ANALYZED IN THE STUDY
P-VALUE
Men number 2,020 2,344
age (years old) 50 (9) 49 (12) 0.001
Body mass index (kg/m2) 23.7 (3.1) 23.9 (3.3) 0.052
Waist circumference (cm) 85.0 (7.9) 86.0 (8.5) 0.063
systolic blood pressure (mmHg) 124 (16) 128 (17) 0.001
diastolic blood pressure (mmHg) 80 (13) 80 (13) 0.752
Trigyceride (mmol/l) 1.39 (0.88) 1.50 (1.09) 0.001
Hdl-cholesterol (mmol/l) 1.42 (0.36) 1.42 (0.39) 0.610
Fasting plasma glucose (mmol/l) 5.28 (0.67) 5.72 (1.67) 0.001
Current smoker (%) 38.5 41.5 0.043
Women number 1,052 1,947
age (years old) 50 (9) 45 (13) 0.001
Body mass index (kg/m2) 22.3 (3.1) 22.2 (3.6) 0.643
Waist circumference (cm) 79.9 (8.9) 80.4 (9.8) 0.143
systolic blood pressure (mmHg) 121 (17) 122 (18) 0.143
diastolic blood pressure (mmHg) 72 (12) 73 (13) 0.099
Trigyceride (mmol/l) 1.02 (0.12) 1.06 (0.21) 0.335
Hdl-cholesterol (mmol/l) 1.76 (0.39) 1.73 (0.39) 0.310
Fasting plasma glucose (mmol/l) 5.00 (0.56) 5.11 (1.00) 0.001
Current smoker (%) 9.0 13.5 0.001
data are presented as the means (standard deviations), otherwise they are presented as proportions.
Abbreviations: Hdl, High-density lipoprotein.
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the  hyperinsulinemic–euglycemic clamp is the  standard 
 technique that is used to measure insulin sensitivity, we used 
the F-IRI concentration as a surrogate measure of insulin 
resistance. Given that our subjects were participants in general 
health check-ups, it was impossible to perform such expen-
sive, invasive, and long-term examinations. F-IRI reflects 
hepatic insulin resistance; however, it has a 70% correlation 
with peripheral insulin resistance.31 Fourth, the questionnaire 
of physical activity, alcohol consumption, and smoking sta-
tus was based on self-reported data, it was customized, and 
it had had not been validated prior to the study. Fifth, our 
study is based on the health examination data regarding bio-
logical markers and lung function, which was obtained at a 
single time, and this might have led to the misclassification 
of individuals.
In conclusion, impaired lung function increased the risk 
of modified IDF-MetS independent of smoking and F-IRI 
concentrations in Japanese men, but not in women.
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